Methenamine Hippurate Tablets Market Report 2025

The methenamine hippurate tablets market size has grown strongly in recent years. It will grow from $9.52 billion in 2024 to $10.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to traditional UTI treatment, antibiotic resistance concerns, clinical validation, physician prescription patterns, patient preference for non-antibiotic solutions.

The methenamine hippurate tablets market size is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing UTI prevalence, rising antibiotic resistance concerns, advancements in UTI management, healthcare focus on preventive therapies, clinical trials and research. Major trends in the forecast period include increased UTI incidence, rising antibiotic resistance, preference for non-antibiotic treatments, focus on preventive healthcare, research and development.

The anticipated increase in the geriatric population is poised to drive the growth of the methenamine hippurate tablets market in the coming years. The geriatric population comprises individuals aged 60 and above, who are more susceptible to urinary tract infections due to factors such as reduced urine flow, enlarged prostate, or kidney stones. Consequently, the demand for methenamine hippurate tablets for treating these conditions is expected to rise. For instance, the World Health Organization reports that by 2030, the percentage of the global population aged 65 and above is expected to rise from 10% in 2022 to 16% in 2050. It is projected that by 2050, Thus, the increasing geriatric population is a key driver for the growth of the methenamine hippurate tablets market.

The increasing incidence of urinary tract infections (UTIs) is projected to drive the growth of the methenamine hippurate tablets market in the future. UTIs are common conditions that arise when bacteria enter the urethra and infect the urinary tract, typically originating from the skin or rectum. Methenamine hippurate tablets are utilized to prevent or treat recurring urinary tract infections caused by specific bacteria. For instance, in October 2023, the National Health Service, a UK-based government department, reported that during the 2022/23 period, there were 147,285 admissions for UTIs as the primary diagnosis. Among these, 56% (82,392) were individuals aged 65 and older, with the highest number of admissions occurring in the 80-84 age group, which accounted for 17,280 admissions. Thus, the rising prevalence of urinary tract infections is fueling the growth of the methenamine hippurate market.

Product innovations have become a significant trend gaining traction in the methenamine hippurate tablets market. Leading companies in this sector are developing innovative products to enhance their market position. For example, in May 2023, EQL Pharma, a European pharmaceutical company specializing in cost-effective generic medicines and niche generics for pharmacies and hospitals, announced the out-licensing of Memprex (methenamine hippurate) to Laboratoires Majorelle for distribution in the French market. This move expands the availability of Memprex and provides a non-antibiotic option for UTI prevention. Laboratoires Majorelle, a prominent player in women's health in France, will market and distribute Memprex, offering an alternative for preventing urinary tract infections.

Strategic collaborations have become a significant avenue for major companies operating in the methenamine hippurate tablets market to enhance profitability. These collaborations involve purposeful partnerships between entities to achieve mutual goals through coordinated efforts, leveraging each other's strengths and resources. In May 2023, EQL Pharma AB, a Swedish pharmaceutical company providing methenamine hippurate tablets, entered into a collaboration with Dr. Pfleger Arzneimittel GmbH. Through this collaboration, EQL Pharma AB aims to launch Methenamine Hippurate with an EQL-registered brand within the next two years, involving standard license fees, regulatory and reimbursement milestones, and a volume-dependent supply price upon regulatory approval. Dr. Pfleger Arzneimittel GmbH is a German pharmaceutical company.

In April 2022, Aurelius Group, a German asset management company, acquired McKesson UK for an undisclosed amount. This acquisition is intended to support growth and development across retail, digital, homecare, and wholesale divisions, expanding the healthcare system to enhance patient outcomes. McKesson UK is a UK-based healthcare company providing methenamine hippurate tablets.

Major companies operating in the methenamine hippurate tablets market include Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., McKesson Corporation, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH.

North America was the largest region in the methenamine hippurate tablets market in 2024. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the methenamine hippurate tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Methenamine hippurate tablets serve as a medication for preventing or controlling recurring urinary tract infections caused by specific bacteria. However, it is not used for treating active infections.

The main types of methenamine hippurate tablets are available in two forms, 20 tablets per bottle and 6 tablets per bottle. Patients can access methenamine hippurate tablets in the form of a 20-tablet bottle. These tablets are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The applications for these tablets include uncomplicated urinary tract infections (UTIs) and healthcare-associated UTIs. The end users encompass hospitals, homecare settings, specialty clinics, and others.

The methenamine hippurate tablets market research report is one of a series of new reports that provides methenamine hippurate tablets market statistics, including methenamine hippurate tablets industry global market size, regional shares, competitors with methenamine hippurate tablets market share, detailed methenamine hippurate tablets market segments, market trends, and opportunities, and any further data you may need to thrive in the methenamine hippurate tablets industry. This methenamine hippurate tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The methenamine hippurate tablets market consists of sales of hexamine hippurate tablets, hiprex tablets, and urinary tract infection tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.